Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma

British Journal of Cancer

Volumn 109, Issue 10, 2013, Pages 2566-2573

  Illidge, T ^a   Chan, C ^a   Counsell, N ^b   Morris, S ^c   Scarisbrick, J ^d   Gilson, D ^e   Popova, B ^b   Patrick, P ^b   Smith, P ^b   Whittaker, S ^c   Cowan, R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; DRY SKIN; EDEMA; FAINTNESS; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL OBSTRUCTION; HUMAN; HYPERLIPIDEMIA; INFECTION; INSOMNIA; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MODIFIED SEVERITY WEIGHTED ASSESSMENT TOOL SCORE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RASH; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; GREAT BRITAIN; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; REMISSION INDUCTION; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES; TREATMENT OUTCOME;

EID: 84887837718     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.616     Document Type: Article

References (31)

1. Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, Scarisbrick JJ (2009) Bexarotene therapy for mycosis fungoides and Sezary syndrome. Br J Dermatol 160: 1299-1307.
2. Bunn Jr. PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann Intern Med 121: 592-602.
3. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL, Olavarria E, Schmitz N, Sureda A (2010) Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 28: 4492-4499.
4. Dummer R, Beyer M, Hymes K, Epping MT, Bernards R, Steinhoff M, Sterry W, Kerl H, Heath K, Ahern JD, Hardwick JS, Garcia-Vargas J, Baumann K, Rizvi S, Frankel SR, Whittaker SJ, Assaf C (2012a) Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition. Leuk Lymphoma 53: 1501-1508.
5. Dummer R, Quaglino P, Becker JC, Hasan B, Karrasch M, Whittaker S, Morris S, Weichenthal M, Stadler R, Bagot M, Cozzio A, Bernengo MG, Knobler R (2012b) Prospective International Multicenter Phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol 30: 4091-4097.
6. Duvic M (2000) Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clin Lymphoma 1(Suppl 1): S51-S55.
7. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C (2010) Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol 28: 2365-2372.
8. Duvic M, Dummer R, Becker JC, Poulalhon N, Ortiz Romero P, Grazia Bernengo M, Lebbe C, Assaf C, Squier M, Williams D, Marshood M, Tai F, Prince HM (2013) Panobinostat activity in both bexarotene-exposed and-naive patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. Eur J Cancer 49(2): 386-394.
9. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, Crowley C, Yocum RC (2001a) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 19: 2456-2471.
10. Duvic M, Kuzel TM, Olsen EA, Martin AG, Foss FM, Kim YH, Heald PW, Bacha P, Nichols J, Liepa A (2002) Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Clin Lymphoma 2: 222-228.
11. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, Yocum RC (2001b) Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 137: 581-593.
12. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N (2006) Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 7: 51-58.
13. Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M, Bisaccia S (2005) Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 23: 5774-5778.
14. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, Burt R (2002) Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma. Arch Dermatol 138: 1359-1365.
15. Jaffe ES, Harris NL, Stein H, Wardiman JW (2001) Pathology and genetics of tumours of the haematopoietic and lymphoid tissues. In The World health Organisation Classification of Tumours. IARC Press: Lyon, France.
16. Kim YH, Chow S, Varghese A, Hoppe RT (1999) Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 135: 26-32.
17. Kurzrock R, Pilat S, Duvic M (1999) Pentostatin therapy of T-cell lymphomas with cutaneous manifestations. J Clin Oncol 17: 3117-3121.
18. Marchi E, Alinari L, Tani M, Stefoni V, Pimpinelli N, Berti E, Pagano L, Bernengo MG, Zaja F, Rupoli S, Pileri S, Baccarani M, Zinzani PL (2005) Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 104: 2437-2441.
19. Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata-Collins J, Forman SJ, Nademanee A (2005) Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol 23: 6163-6171.
20. Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC (2011) Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 29: 2598-2607.
21. Quereux G, Marques S, Nguyen JM, Bedane C, D'Incan M, Dereure O, Puzenat E, Claudy A, Martin L, Joly P, Delaunay M, Beylot-Barry M, Vabres P, Celerier P, Sasolas B, Grange F, Khammari A, Dreno B (2008) Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sezary syndrome. Arch Dermatol 144: 727-733.
22. Rosen ST, Foss FM (1995) Chemotherapy for mycosis fungoides and the Sezary syndrome. Hematol Oncol Clin North Am 9: 1109-1116.
23. Saleh MN, LeMaistre CF, Kuzel TM, Foss F, Platanias LC, Schwartz G, Ratain M, Rook A, Freytes CO, Craig F, Reuben J, Sams MW, Nichols JC (1998) Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 39: 63-73.
24. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10: 1-10.
25. Stevens SR, Ke MS, Parry EJ, Mark J, Cooper KD (2002) Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 138: 42-48.
26. Strauss DJ, Horwitz SM, Hymes KB, Goy A, Hernandez-Ilizaliturri FJ, Feldman T, Wegner B, Myskowski P (2011) Final results of phase ii trial of pegylated liposomal doxorubicin (PLD) followed by bexarotene (Bex) in advanced cutaneous T-cell lymphoma (CTCL). ASH: San Diego.
27. Weinstock MA, Horm JW (1988) Mycosis fungoides in the United States. Increasing incidence and descriptive epidemiology. JAMA 260: 42-46.
28. Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH (2010) Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 28: 4485-4491.
29. Zackheim HS, Epstein Jr. EH (1989) Low-dose methotrexate for the Sezary syndrome. J Am Acad Dermatol 21: 757-762.
30. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, Orcioni GF, Ascani S, Simoni R, Pileri SA, Tura S (2000) Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 18: 2603-2606.
31. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M (2010) Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol 21: 860-863.